Kit and method for simultaneously detecting 18 steroid hormones based on biderivatization technology

Through dual-derivative technology and high-performance liquid chromatography tandem mass spectrometry, the problems of low sensitivity and high cost in steroid hormone detection are solved, and the simultaneous detection of multiple steroid hormones, including estrogen, is realized on a conventional platform, reducing the detection cost and expand clinical applicability.

CN118961985AActive Publication Date: 2024-11-15SHANGHAI WANZI HEALTH MEDICAL LAB CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411126981.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-15
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

The prior art has low sensitivity and high cost in steroid hormone detection, and cannot detect multiple steroid hormones at the same time, especially estrogen and other steroid hormones, which require high-end mass spectrometers and cumbersome sample processing processes.

Method used

Using dual-derivative technology and high-performance liquid chromatography tandem mass spectrometry, the simultaneous detection of 18 steroid hormones, including estrogen and others, is achieved through the dual-derivative method of hydroxylamine hydrochloride and 1,2-dimethylimidazole-5-sulfonyl chloride. Steroid hormones reduce the performance requirements of the mass spectrometer and the complexity of sample processing.

Benefits of technology

It has achieved efficient and low-cost detection of multiple steroid hormones simultaneously on conventional liquid chromatography-tandem mass spectrometry platforms, reducing detection costs and expanding the clinical applicability and throughput of steroid hormone detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961985A_ABST
    Figure CN118961985A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of clinical examination, and particularly relates to a kit and a method for simultaneously detecting 18 steroid hormones based on a biderivatization technology. Respectively adding an internal standard solution into the series of calibrator working solutions, the series of quality control working solutions and the serum sample; then adding a protein precipitant and a sample extracting solution into each sample, and adding a sample enhancing solution 1 into the extracting solution to carry out oximation reaction; continuously adding a sample enhancing solution 2 and a sample adjusting solution for esterification reaction; and after the reaction is finished, centrifuging the reaction liquid, taking the supernatant, and carrying out LC-MS / MS detection on the supernatant. According to the present invention, the multiple steroid hormones are simultaneously detected by using the dual-derivation method, the positive-negative switching is not required during the mass spectrometry detection, the high-value consumables such as the magnetic beads or the SPE are not required, the simultaneous detection of the estrogen and the other steroid hormones on the conventional liquid chromatography-tandem mass spectrometry platform can be achieved, and the clinical applicability of the steroid hormone detection method is expanded.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of clinical testing, and relates to a clinical detection kit and method for steroid hormones, and specifically to a kit and method for simultaneously detecting 18 types of steroid hormones based on double derivatization technology. Background Art

[0002] Steroid hormones are a class of fat-soluble hormones synthesized from cholesterol, including testosterone, estradiol, progesterone, etc. They play an important regulatory role in the human body. Abnormal levels of steroid hormones may be related to abnormalities of other steroid hormones, so simultaneous detection of multiple steroid hormones can provide a more comprehensive endocrine function assessment and help identify potential problems. At present, liquid chromatography-tandem mass spectrometry has unparalleled advantages over other methods in the detection of steroid hormones, but it still faces considerable challenges.

[0003] An important factor is that some steroid hormones not only have extremely low concentrations in the human body, but also have low ionization efficiency of compound molecules, resulting in poor sensitivity. At present, only high-end mass spectrometers such as AB SCIEX 6500 and Waters xevo-TQS can achieve picogram-level steroid hormone detection, and the detection conditions are too harsh. Another challenge is that aldosterone and estradiol, estriol and other estrogens not only have extremely low concentrations in the human body, but also require negative ion scanning mode scanning during mass spectrometry detection. Therefore, when aldosterone, estradiol, estriol and other steroids are detected simultaneously, the mass spectrometer needs to have a faster positive and negative mode switching speed, otherwise it may not be able to collect enough scanning points within the chromatographic peak width time, thereby affecting the quantitative accuracy, which also places high demands on the performance of the mass spectrometer. In addition, enrichment technology is required for sample processing, which is not only complicated to operate, but also requires expensive solid phase extraction or magnetic bead consumables, which also restricts the promotion of steroid hormone detection services in clinical laboratories.

[0004] One solution to the low sensitivity and high cost of steroid hormone detection is to use derivatization to increase the intensity of mass spectrometry signals. For example, some literature reports that the use of hydroxylamine and Girard reagents to undergo derivatization reactions with carbonyl-containing steroid hormones can significantly improve the sensitivity of mass spectrometry, but such derivatization reagents cannot undergo derivatization reactions with compounds that do not contain carbonyl structures, such as estradiol and estriol. There are also literature reports that dansyl chloride can be used to undergo derivatization reactions with the phenolic hydroxyl functional groups of estradiol and estriol, but such derivatization reagents cannot undergo derivatization reactions with most steroid hormones other than estrogen, making it impossible to simultaneously use the derivatization method to detect hormones containing phenolic hydroxyl groups and other hormones. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a kit for simultaneously detecting 18 types of steroid hormones based on double derivatization technology in view of the deficiencies of the prior art.

[0006] The technical problem that the present invention also solves is to provide the use of the above-mentioned kit in detecting steroid hormones in serum using high performance liquid chromatography tandem mass spectrometry technology.

[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0008] The present invention provides a kit for simultaneously detecting 18 kinds of steroid hormones based on double derivatization technology, wherein the steroid hormones are 11-deoxycortisol, dehydroepiandrosterone, corticosterone, 18-hydroxycorticosterone, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, estriol and dehydroepiandrosterone sulfate;

[0009] The kit comprises the following reagents:

[0010] (1) Series of Calibrators:

[0011] The series of calibration products are freeze-dried products of series of calibration product working solutions with six different concentration levels, and the series of calibration product working solutions are calibration product working solutions with six different concentration levels prepared by diluting a steroid hormone mixed working solution of known concentration with a second solvent;

[0012] Among them, the six concentration levels of the calibrator working solution are:

[0013] The concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were the same, and the six concentrations were 0.05 ng / mL, 0.125 ng / mL, 0.25 ng / mL, 1.25 ng / mL, 5 ng / mL, and 10 ng / mL;

[0014] The concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were the same, and the six concentrations were 0.1 ng / mL, 0.25 ng / mL, 0.5 ng / mL, 2.5 ng / mL, 10 ng / mL, and 20 ng / mL;

[0015] The concentrations of estrone and 18-hydroxycorticosterone were the same, and the six concentrations were 0.02 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.5 ng / mL, 2 ng / mL, and 4 ng / mL;

[0016] The six concentrations of dehydroepiandrosterone sulfate are: 50ng / mL, 125ng / mL, 250ng / mL, 1250ng / mL, 5000ng / mL, and 10000ng / mL;

[0017] The six concentrations of cortisol were: 1 ng / mL, 2.5 ng / mL, 5 ng / mL, 25 ng / mL, 100 ng / mL, and 200 ng / mL;

[0018] (2) Series of quality control products:

[0019] The series of quality control products are freeze-dried products of a series of quality control product working solutions with two different concentration levels, and the series of quality control product working solutions are quality control product working solutions with two different concentration levels prepared by diluting a steroid hormone mixed working solution of known concentration with a second solvent;

[0020] Among them, the two concentration levels of the quality control working solution are:

[0021] The concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were the same, with two concentration points of 0.2 ng / mL and 7.5 ng / mL, respectively;

[0022] The concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were the same, with two concentration points of 0.4 ng / mL and 15 ng / mL, respectively;

[0023] The concentrations of estrone and 18-hydroxycorticosterone were the same, with the two concentration points being 0.08 ng / mL and 3 ng / mL, respectively;

[0024] The two concentration points of dehydroepiandrosterone sulfate were 200 ng / mL and 7500 ng / mL;

[0025] The 2 concentration points of cortisol are: The 2 concentration points of cortisol are 4ng / mL and 150ng / mL;

[0026] (3) Internal standard solution:

[0027] The internal standard solution is a mixture of various steroid hormone standard internal standard stock solutions of known concentrations, and is diluted with a third solvent to form an internal standard solution;

[0028] In the internal standard solution, the concentrations of 11-deoxycortisol-d5, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, corticosterone-d8, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, 18-hydroxycorticosterone-d4, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 are 200 ng / mL, the concentration of dehydroepiandrosterone-d6 is 1 μg / mL, and the concentration of dehydroepiandrosterone sulfate-d6 is 4 μg / mL;

[0029] (4) Sample extraction solution: any one or a combination of n-hexane, methyl tert-butyl ether and ethyl acetate;

[0030] (5) Protein precipitant: a mixed solvent of acetonitrile and methanol in any volume ratio;

[0031] (6) Sample conditioning solution: a mixed solution of 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution in a volume ratio of 1:9 to 9:1;

[0032] (7) Sample enhancement solution 1: hydroxylamine hydrochloride solution, the solvent in the solution is 10vt% to 20vt% methanol aqueous solution or 10vt% to 20vt% acetonitrile aqueous solution, and the concentration of hydroxylamine hydrochloride in the solution is 0.5mol / L to 5mol / L;

[0033] (8) Sample enhancement solution 2: 1,2-dimethylimidazole-5-sulfonyl chloride solution, the solvent in the solution is acetone or ethyl acetate, and the concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the solution is 0.2 mg / mL to 5 mg / mL;

[0034] (9) Mobile phase A: 0.1 vt% formic acid aqueous solution;

[0035] (10) Mobile phase B: methanol solution containing 0.1 vt% formic acid or acetonitrile solution containing 0.1 vt% formic acid;

[0036] The calibrator and the quality control product are freeze-dried using the same freeze-drying process, and the freeze-drying process sequentially includes a pre-freezing stage, sublimation drying and analytical drying;

[0037] The operating conditions of the pre-freezing stage are shown in Table 1:

[0038] Table 1

[0039]

[0040]

[0041] The operating conditions of the sublimation drying are shown in Table 2:

[0042] Table 2

[0043]

[0044] The operating conditions of the analytical drying are shown in Table 3:

[0045] Table 3

[0046]

[0047] or,

[0048] The calibrator and the quality control product are freeze-dried using the same freeze-drying process, and the freeze-drying process sequentially includes a pre-freezing stage, sublimation drying and analytical drying;

[0049] The operating conditions of the pre-freezing stage are shown in Table 4:

[0050] Table 4

[0051]

[0052] The operating conditions of the sublimation drying are shown in Table 5:

[0053] Table 5

[0054]

[0055] The operating conditions of the analytical drying are shown in Table 6:

[0056] Table 6

[0057]

[0058] In some embodiments, the second solvent consists of bovine serum albumin, an antioxidant, a preservative, a buffer and water; the antioxidant is isoascorbic acid; the preservative is citric acid; the buffer is PBS buffer; preferably, the second solvent consists of 1-5% bovine serum albumin, 0.05%-2% isoascorbic acid, 0.05%-2% citric acid, 10% 10×PBS buffer and deionized water; further preferably, the second solvent consists of 1% bovine serum albumin, 0.1% isoascorbic acid, 0.1% citric acid, 10% 10×PBS buffer and deionized water; the third solvent is a mixed solvent of methanol, acetonitrile and isopropanol in any volume ratio; preferably, the third solvent is a mixed solvent of methanol, acetonitrile and isopropanol in a volume ratio of 3:6:1.

[0059] Wherein, when the steroid hormone mixed working solution of known concentration is mixed with the second solvent, the added proportion of the steroid hormone mixed working solution does not exceed 5% of the total volume.

[0060] In some embodiments, the steroid hormone mixed working solution of known concentration is prepared as follows:

[0061] 11-deoxycortisol, dehydroepiandrosterone, cortisol, 18-hydroxycortisol, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, and estriol were accurately weighed, dissolved in the first solvent, and prepared into 1 mg / mL standard stock solutions; dehydroepiandrosterone sulfate was accurately weighed, dissolved in the first solvent, and prepared into 2 mg / mL standard stock solutions;

[0062] The above-mentioned standard stock solutions are then prepared into a steroid hormone mixed working solution with the first solvent; the concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone and testosterone in the steroid hormone mixed working solution are all 1 μg / mL; the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone and dehydroepiandrosterone are all 2 μg / mL; the concentrations of estrone and 18-hydroxycorticosterone are both 400 ng / mL; the concentration of dehydroepiandrosterone sulfate is 1 mg / mL, and the concentration of cortisol is 20 μg / mL.

[0063] In some embodiments, the known concentrations of various steroid hormone standard internal standard stock solutions are prepared as follows:

[0064] 11-deoxycortisol-d5, dehydroepiandrosterone-d6, cortisol-d8, and 18-hydroxycortisol-d4 were accurately weighed and dissolved in the first solvent to prepare 1 mg / mL standard internal standard stock solutions; dehydroepiandrosterone sulfate-d6 was accurately weighed and dissolved in the first solvent to prepare 2 mg / mL standard internal standard stock solutions; pregnenolone-d4, 17-hydroxypregnenolone-d3, 17-hydroxyprogesterone-d8, progesterone-d9, cortisol-d4, 21-deoxycortisol-d8, aldosterone-d7, testosterone-d3, androstenedione-d7, corticosterone-d 8、 Estrone-d4, estradiol-d5, and estriol-d3 are respectively dissolved in the first solvent and prepared into 100 μg / mL standard internal standard stock solutions;

[0065] The above-mentioned internal standard stock solutions are mixed and diluted with the third solvent to obtain the internal standard solution.

[0066] In some embodiments, the first solvent is a methanol solution containing 2,6-di-tert-butyl-4-methylphenol; preferably, in the methanol solution containing 2,6-di-tert-butyl-4-methylphenol, the mass volume ratio of 2,6-di-tert-butyl-4-methylphenol to methanol is 1 g:1000 mL.

[0067] In some embodiments, the series of calibrators and the series of quality control working solutions are freeze-dried separately to obtain the series of calibrators and the series of quality control products.

[0068] In some embodiments, preferably, the sample extract is n-hexane; the protein precipitant is a mixed solvent of acetonitrile and methanol in a volume ratio of 9:1; the sample conditioning solution is a mixed solution of 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution in a volume ratio of 6:4; the sample enhancement solution 1 is a hydroxylamine hydrochloride solution, the solvent in the solution is 20 vt% methanol aqueous solution, and the concentration of hydroxylamine hydrochloride in the solution is 1 mol / L; the sample enhancement solution 2 is a 1,2-dimethylimidazole-5-sulfonyl chloride solution, the solvent in the solution is acetone, and the concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the solution is 1 mg / mL; the mobile phase A is a 0.1 vt% formic acid aqueous solution; the mobile phase B is a methanol solution containing 0.1 vt% formic acid.

[0069] In some embodiments, preferably, the calibrator and the quality control are freeze-dried using the same freeze-drying process, and the freeze-drying process sequentially includes a pre-freezing stage, sublimation drying and analytical drying; wherein the operating conditions of the pre-freezing stage are shown in Table 4; the operating conditions of the sublimation drying are shown in Table 5; and the operating conditions of the analytical drying are shown in Table 6.

[0070] The use of the above-mentioned kit in the simultaneous detection of 18 steroid hormones in serum using high performance liquid chromatography tandem mass spectrometry is also within the protection scope of the present invention.

[0071] Specifically, the 18 steroid hormones are 11-deoxycortisol, dehydroepiandrosterone, corticosterone, 18-hydroxycorticosterone, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, estriol and dehydroepiandrosterone sulfate;

[0072] Before the determination of steroid hormones, the series of calibrators are reconstituted with ultrapure water according to the corresponding six concentration levels of the series of calibrator working solutions to obtain series of calibrator working solutions; the series of quality control products are reconstituted with ultrapure water according to the corresponding two concentration levels of the series of quality control working solutions to obtain series of quality control working solutions.

[0073] The kit is stored at -20°C and is taken out from -20°C when in use. After returning to room temperature, the components in the kit are taken out.

[0074] Specifically, the steps of detecting 18 steroid hormones in serum include:

[0075] The internal standard solution is added to the series of calibration solution, the series of quality control solution and the serum sample respectively; then a protein precipitant and a sample extract are added to each sample, centrifuged and the supernatant is taken; the supernatant is blown dry, and after adding the sample enhancement solution 1, an oximation reaction is carried out at 55-65° C.; the sample enhancement solution 2 and the sample adjustment solution are continuously added, and an esterification reaction is carried out at 55-65° C.; after the reaction is completed, the reaction solution is centrifuged, the supernatant is taken, and the supernatant is subjected to LC-MS / MS detection.

[0076] Specifically, preferably, the step of detecting 18 types of steroid hormones in serum comprises:

[0077] 20 μL of internal standard solution was added to 0.3 mL of the series of calibration solution, 0.3 mL of the series of quality control solution, and 0.3 mL of serum sample, respectively; then 0.3 mL of protein precipitant and 1.2 mL of sample extract were added to each sample, and the mixture was stirred at 12000 r·min. -1 Centrifuge for 5 minutes and take the supernatant; blow dry the supernatant with nitrogen at 40°C, add 80 μL sample enhancement solution 1 and perform oximation reaction at 60°C for 15 minutes; continue to add 40 μL sample enhancement solution 2 and 30 μL sample adjustment solution, and perform esterification reaction at 60°C for 15 minutes; after the reaction, the reaction solution is rotated at 12000 r·min -1 Centrifuge for 3 min, take the supernatant, and perform LC-MS / MS detection on the supernatant.

[0078] Among them, the six concentration levels of the calibrator working solution are:

[0079] The concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were the same, and the six concentrations were 0.05 ng / mL, 0.125 ng / mL, 0.25 ng / mL, 1.25 ng / mL, 5 ng / mL, and 10 ng / mL;

[0080] The concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were the same, and the six concentrations were 0.1 ng / mL, 0.25 ng / mL, 0.5 ng / mL, 2.5 ng / mL, 10 ng / mL, and 20 ng / mL;

[0081] The concentrations of estrone and 18-hydroxycorticosterone were the same, and the six concentrations were 0.02 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.5 ng / mL, 2 ng / mL, and 4 ng / mL;

[0082] The six concentrations of dehydroepiandrosterone sulfate are: 50ng / mL, 125ng / mL, 250ng / mL, 1250ng / mL, 5000ng / mL, and 10000ng / mL;

[0083] The six concentrations of cortisol are: 1ng / mL, 2.5ng / mL, 5ng / mL, 25ng / mL, 100ng / mL, and 200ng / mL.

[0084] Among them, the two concentration levels of the quality control working solution are:

[0085] The concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were the same, with two concentration points of 0.2 ng / mL and 7.5 ng / mL, respectively;

[0086] The concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were the same, with two concentration points of 0.4 ng / mL and 15 ng / mL, respectively;

[0087] The concentrations of estrone and 18-hydroxycorticosterone were the same, with the two concentration points being 0.08 ng / mL and 3 ng / mL, respectively;

[0088] The two concentration points of dehydroepiandrosterone sulfate were 200 ng / mL and 7500 ng / mL;

[0089] The two concentration points of cortisol are: 4 ng / mL and 150 ng / mL.

[0090] Among them, the concentrations of 11-deoxycortisol-d5, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, corticosteroid-d8, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, 18-hydroxycorticosterone-d4, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 in the internal standard solution are 200 ng / mL, the concentration of dehydroepiandrosterone-d6 is 1 μg / mL, and the concentration of dehydroepiandrosterone sulfate-d6 is 4 μg / mL.

[0091] The sample extract is any one or a combination of n-hexane, methyl tert-butyl ether and ethyl acetate, preferably n-hexane.

[0092] The protein precipitant is a mixed solvent of acetonitrile and methanol in any volume ratio, preferably a mixed solvent of acetonitrile and methanol in a volume ratio of 9:1.

[0093] The sample conditioning solution is a mixed solution of 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution in a volume ratio of 1:9 to 9:1, preferably a mixed solution of 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution in a volume ratio of 6:4.

[0094] Wherein, the sample enhancement solution 1 is a hydroxylamine hydrochloride solution, the solvent in the solution is a 10vt% to 20vt% methanol aqueous solution or a 10vt% to 20vt% acetonitrile aqueous solution, and the concentration of hydroxylamine hydrochloride in the solution is 0.5mol / L to 5mol / L; preferably, the sample enhancement solution 1 is a hydroxylamine hydrochloride solution, the solvent in the solution is a 20vt% methanol aqueous solution, and the concentration of hydroxylamine hydrochloride in the solution is 1mol / L.

[0095] Wherein, the sample enhancement liquid 2 is a 1,2-dimethylimidazole-5-sulfonyl chloride solution, the solvent in the solution is acetone or ethyl acetate, and the concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the solution is 0.2 mg / mL to 5 mg / mL; preferably, the sample enhancement liquid 2 is a 1,2-dimethylimidazole-5-sulfonyl chloride solution, the solvent in the solution is acetone, and the concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the solution is 1 mg / mL; the mobile phase A is a 0.1 vt% formic acid aqueous solution; the mobile phase B is a methanol solution containing 0.1 vt% formic acid.

[0096] Specifically, the chromatographic conditions for the LC-MS / MS detection are as follows:

[0097] Liquid chromatography conditions: Chromatographic column: Fei Nuo Mei C8 ( 100×2.1mm, 2.6μm), Fenome C18 ( 100×3mm, 2.6μm) or Waters BEH C18 (2.1mm×50mm, 1.7μm); column temperature: 40℃; mobile phase A: aqueous solution containing 0.1vt% formic acid; mobile phase B: methanol solution containing 0.1vt% formic acid or acetonitrile solution containing 0.1vt% formic acid; gradient elution; elution gradient: 0~0.5min, mobile phase B is 35%; 0.5~5.0min, mobile phase B is from 35% to 100%; 5.0~5.1min, mobile phase B is 100% to 35%; 5.1~7.0min, mobile phase B is 35%; injection volume is 20μL; acquisition time is 7min;

[0098] Mass spectrometry conditions: electrospray ion source, collection mode is positive ion mode, spray voltage is 3500-5500 V, sheath gas pressure: 35-50 Arb; auxiliary gas pressure: 6-10 Arb; evaporation temperature: 450-500 ° C; ion transfer tube temperature: 350-400 ° C, collection mode is multiple reaction monitoring mode, collection time 7 min;

[0099] Preferably, the chromatographic conditions for the LC-MS / MS detection are as follows:

[0100] Liquid chromatography conditions: Chromatographic column: Fei Nuo Mei C8 ( 100×2.1mm, 2.6μm); column temperature: 40℃; mobile phase A: aqueous solution containing 0.1vt% formic acid; mobile phase B: methanol solution containing 0.1vt% formic acid; gradient elution; elution gradient: 0~0.5min, mobile phase B is 35%; 0.5~5.0min, mobile phase B is from 35% to 100%; 5.0~5.1min, mobile phase B is 100% to 35%; 5.1~7.0min, mobile phase B is 35%; injection volume is 20μL; acquisition time is 7min;

[0101] The mass spectrometry chromatography conditions are as follows: an electrospray ion source is used, the collection mode is a positive ion mode, the spray voltage is 3500V, the sheath gas pressure is 40Arb, the auxiliary gas pressure is 10Arb, the evaporation temperature is 450°C, the ion transfer tube temperature is 350°C, the collection mode is a multiple reaction monitoring mode, and the collection time is 7min.

[0102] Beneficial effects:

[0103] (1) The present invention adopts a double derivatization method to simultaneously detect multiple steroid hormones. No positive or negative switching is required during mass spectrometry detection, and no high-value consumables such as magnetic beads or SPE are required. It can achieve simultaneous detection of estrogen and other steroid hormones on a conventional liquid chromatography-tandem mass spectrometry platform (such as TSQquantis, sciex 4500, etc.), expanding the clinical applicability of steroid hormone detection methods.

[0104] (2) The present invention prepares a steroid hormone detection kit that does not contain consumables such as magnetic beads and SPE, which is used for the detection of various steroid hormones including estrogen, greatly reducing the detection cost.

[0105] (3) In the prior art, the non-derivatization method generally requires the use of solid phase extraction columns or solid phase extraction plates during sample processing, which not only has high consumables costs, but also has cumbersome operations. It is necessary to control the volume, flow rate and pressure of the eluent. The non-derivatization method has low sensitivity. Some hormones with concentrations at the picogram level need to be detected by relatively high-end instruments, and the instrument needs to be able to quickly realize the positive and negative switching function, which limits the development of steroid hormone detection. The derivatization method cannot detect estrogen and other hormones at the same time, and can only divide the sample into two parts to detect estrogen and other hormones respectively. The kit provided by the present invention does not require SPE and can be directly used for the detection of 18 steroid hormones in human serum. The kit provided by the present invention greatly saves the detection cost and improves the detection throughput; the detection using the kit provided by the present invention does not require high sensitivity of the mass spectrometer, such as AB SCIEX 4500, TSQ quantis instruments, which can reduce the detection cost and expand the clinical development of steroid hormones.

[0106] (4) The kit provided by the present invention uses 1,2-dimethylimidazole-5-sulfonyl chloride (DMIS) instead of dansyl chloride in the prior art as the derivatization reagent for estrogen, thereby solving the problems of dansyl chloride ion inhibition and poor specificity. The present invention adopts double derivatization technology, which solves the problem that the traditional derivatization method cannot simultaneously detect estrogen and other steroid hormones, and can simultaneously detect androgens, estrogens and progestins at one time without the need for positive and negative switching. BRIEF DESCRIPTION OF THE DRAWINGS

[0107] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.

[0108] Figure 1 It is a typical derivatization reaction principle of steroid hormones; among them, route a is the oximation reaction principle of carbonyl-containing steroid compounds, and route b is the esterification reaction principle of steroid hormones containing phenolic hydroxyl groups.

[0109] Figure 2 is the effect of different concentrations of hydroxylamine hydrochloride solution on the mass spectrometric response of aldosterone; Figure 2 The concentration of hydroxylamine hydrochloride solution in a is 0.5 mol / L; Figure 2 The concentration of hydroxylamine hydrochloride solution in b is 1 mol / L; Figure 2 The concentration of hydroxylamine hydrochloride solution in c is 2 mol / L.

[0110] Figure 3 The effect of different concentrations of 1,2-dimethylimidazole-5-sulfonyl chloride on the mass spectrometric response of estrone, estradiol, and estriol; Figure 3a is the effect of 0.5 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution on the mass spectrometric response of estrone, estradiol, and estriol; Figure 3 b is the effect of 1 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution on the mass spectrometric response of estrone, estradiol, and estriol; Figure 3 c is the effect of 2 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution on the mass spectrometric response of estrone, estradiol and estriol.

[0111] Figure 4 The effect of buffer solutions composed of different ratios of sodium carbonate solution and sodium bicarbonate solution on the mass spectrometric response of estrone, estradiol and estriol; Figure 4 a is the effect of buffer 1 on the mass spectrometric responses of estrone, estradiol and estriol; Figure 4 b is the effect of buffer 2 on the mass spectrometric response of estrone, estradiol and estriol; Figure 4 c is the effect of buffer 3 on the mass spectrometric response of estrone, estradiol and estriol.

[0112] Figure 5 is the effect of different chromatographic columns on the mass spectrometric response of estrone, estradiol and estriol; Figure 5 a is Fei Nuo Mei C8 ( The effect of the 100×2.1mm, 2.6μm) column on the mass spectrometric response of estrone, estradiol and estriol; Figure 5 b is Fenomime C18 ( 100×3mm, 2.6μm) on the mass spectrometric response of estrone, estradiol and estriol; Figure 5 c shows the effect of Waters BEHC18 (2.1 mm × 50 mm, 1.7 μm) on the mass spectrometric response of estrone, estradiol and estriol.

[0113] Figure 6 The extracted ion chromatograms of 18 steroid hormones at the quantitative limit concentration.

[0114] Figure 7 The linearity and lower limit of quantitation data of 18 steroid hormones are shown in Figure 2. DETAILED DESCRIPTION

[0115] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0116] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0117] In order to achieve these purposes and other advantages according to the present invention, a liquid chromatography-mass spectrometry method based on double derivatization technology is provided to simultaneously detect multiple steroid hormones including estrogen, and the implementation path comprises the following steps:

[0118] The first solvent used in this embodiment is a methanol solution containing 2,6-di-tert-butyl-4-methylphenol, and the mass volume ratio of 2,6-di-tert-butyl-4-methylphenol to methanol is 1 g:1000 mL.

[0119] The typical derivatization reaction principle of steroid hormones in the embodiments of the present invention is as follows: Figure 1 As shown; wherein, route a is the oximation reaction principle of carbonyl-containing steroid compounds, and route b is the esterification reaction principle of steroid hormones containing phenolic hydroxyl groups.

[0120] The bovine serum albumin used in the examples of the present invention was purchased from Sigma, with the catalog number: B2064.

[0121] Embodiment 1:

[0122] 1. Preparation of reagents

[0123] Before establishing LC-MS / MS, steroid hormone standards need to be prepared into stock solutions and mixed working solutions.

[0124] 1.1. Preparation of stock liquid

[0125] (1) Preparation of standard stock solution:

[0126] 11-deoxycortisol, dehydroepiandrosterone, cortisol, 18-hydroxycortisol, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, and estriol were accurately weighed, dissolved in the first solvent, and then fixed to volume to prepare a single standard stock solution of 1 mg / mL. Dehydroepiandrosterone sulfate was accurately weighed, dissolved in the first solvent, and then fixed to volume to prepare a single standard stock solution of 2 mg / mL.

[0127] (2) Preparation of standard internal standard stock solution:

[0128] Accurately weigh 11-deoxycortisol-d5, dehydroepiandrosterone-d6, cortisol-d8, and 18-hydroxycorticosterone-d4, each with a standard specification of 1 mg. Add 1 mL of the first solvent to dissolve them, and then prepare a single standard internal standard stock solution of 1 mg / mL.

[0129] Accurately weigh 2 mg of dehydroepiandrosterone sulfate-d6 and add it to the first solvent to dissolve it to prepare a 2 mg / mL single standard internal standard stock solution.

[0130] Precisely weigh pregnenolone-d4, 17-hydroxypregnenolone-d3, 17-hydroxyprogesterone-d8, progesterone-d9, cortisol-d4, 21-deoxycortisol-d8, aldosterone-d7, testosterone-d3, androstenedione-d7, corticosterone-d 8、 Estrone-d4, estradiol-d5, and estriol-d3 were respectively added to the first solvent for dissolution to prepare single standard internal standard stock solutions of 100 μg / mL.

[0131] 1.2. Preparation of mixed working solution

[0132] Take 10 μL of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone and testosterone standard stock solutions; 20 μL of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone and dehydroepiandrosterone standard stock solutions; 4 μL of estrone and 18-hydroxycorticosterone standard stock solutions, 5 mL of dehydroepiandrosterone sulfate standard stock solution, and 200 μL of cortisol standard stock solution are placed in a 10 mL volumetric flask, and the first solvent is added to the fixed volume to prepare a mixed working solution of 18 steroid hormones, among which pregnenolone, progesterone, The concentrations of estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were all 1 μg / mL; the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were all 2 μg / mL; the concentrations of estrone and 18-hydroxycorticosterone were both 400 ng / mL; the concentration of dehydroepiandrosterone sulfate was 1 mg / mL, and the concentration of cortisol was 20 μg / mL.

[0133] 1.3. Preparation of mixed internal standard working solution

[0134] Take 5 μL of 11-deoxycortisol-d5, cortisol-d8 and 18-hydroxycortisol-d4 standard internal standard stock solutions, 25 μL of dehydroepiandrosterone-d6 standard internal standard stock solution and 50 μL of dehydroepiandrosterone sulfate-d6, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 standard internal standard stock solutions respectively, place them in a 25 mL volumetric flask, and use the first solution to dissolve the solution in water. The volume was fixed with a volumetric agent to prepare a mixed internal standard working solution; wherein the concentration of 11-deoxycortisol-d5, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, corticosterone-d8, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, 18-hydroxycorticosterone-d4, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 was 200 ng / mL, the concentration of dehydroepiandrosterone-d6 was 1 μg / mL, and the concentration of dehydroepiandrosterone sulfate-d6 was 4 μg / mL.

[0135] 1.4 Preparation of Calibrator Solutions and Quality Control Products

[0136] The mixed working solution was diluted 20,000 times, 8,000 times, 4,000 times, 800 times, 200 times and 100 times with the second solvent to prepare calibration products with 6 concentration points. The mixed working solution was diluted 5,000 times and 133.33 times with the second solvent to prepare quality control products with 2 concentration points. Among them, the second solvent is composed of bovine serum albumin, isoascorbic acid, citric acid, 10×PBS buffer, and deionized water; among them, the concentration of bovine serum albumin is 1% (m / v), the concentration of isoascorbic acid is 0.1% (m / v), the concentration of citric acid is 0.1% (m / v), the volume proportion of 10×PBS in the second solvent is 10%, and the remainder is deionized water. Among them, the unit of m / v is g / mL.

[0137] The six concentration points of the calibration solution are: pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone have the same concentration, and the six concentrations are 0.05 ng / mL, 0.125 ng / mL, 0.25 ng / mL, 1.25 ng / mL, 5 ng / mL, and 10 ng / mL, respectively.

[0138] The two concentration points of the quality control product are: the concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone are the same, and the two concentration points are 0.2 ng / mL and 7.5 ng / mL, respectively.

[0139] The six concentration points of the calibration solution are: 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, cortisol, androstenedione, corticosterone, and dehydroepiandrosterone have the same concentration, and the six concentrations are 0.1 ng / mL, 0.25 ng / mL, 0.5 ng / mL, 2.5 ng / mL, 10 ng / mL, and 20 ng / mL, respectively.

[0140] The two concentration points of the quality control product are: the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, cortisol, androstenedione, corticosterone, and dehydroepiandrosterone are the same, and the two concentration points are 0.4 ng / mL and 15 ng / mL, respectively.

[0141] The six concentration points of the calibration solution are: the concentrations of estrone and 18-hydroxycorticosterone are the same, and the six concentrations are 0.02 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.5 ng / mL, 2 ng / mL, and 4 ng / mL, respectively.

[0142] The two concentration points of the quality control product are: the concentrations of estrone and 18-hydroxycorticosterone are the same, and the two concentration points are 0.08 ng / mL and 3 ng / mL respectively.

[0143] The six concentration points of the calibration solution are: the six concentrations of dehydroepiandrosterone sulfate are: 50 ng / mL, 125 ng / mL, 250 ng / mL, 1250 ng / mL, 5000 ng / mL, and 10000 ng / mL.

[0144] The two concentration points of the quality control product are: the two concentration points of dehydroepiandrosterone sulfate are 200 ng / mL and 7500 ng / mL respectively.

[0145] The six concentration points of the calibration solution are: the six concentrations of cortisol are: 1 ng / mL, 2.5 ng / mL, 5 ng / mL, 25 ng / mL, 100 ng / mL, and 200 ng / mL.

[0146] The two concentration points of the quality control product are: the two concentration points of cortisol are 4 ng / mL and 150 ng / mL respectively.

[0147] 2. Optimization of mass spectrometry conditions

[0148] 2.1. Screening of carbonyl derivatization reagents

[0149] There are many kinds of carbon-based derivatization reagents commonly used in the prior art, such as hydroxylamine hydrochloride, methoxyamine, Girard reagent T, Girard reagent P, etc. Hydroxylamine hydrochloride, methoxyamine, Girard reagent T, and Girard reagent P can all undergo derivatization reactions with carbonyl groups. Among them, the derivatization conditions of methoxyamine are relatively harsh, and it is necessary to incubate in a 60°C water bath for 30 minutes (https: / / doi.org / 10.1016 / j.chroma.2019.460709). Girard reagent T and Girard reagent P can greatly improve the mass spectrometry response of steroids after reacting with hydroxylamine, but the excess Girard reagent is difficult to remove, resulting in a significant matrix effect (http: / / dx.doi.org / 10.1016 / j.trac.2012.10.003), and SPE is required to remove interference. Therefore, preferably, hydroxylamine hydrochloride is selected as the carbonylation derivatization reagent.

[0150] Pregnenolone (P5), 17-hydroxypregnenolone (17OHP5), 17-hydroxyprogesterone (17α-Hydroxyprogesterone, 17OHP4), progesterone (P4), cortisol (F), 21-deoxycortisol (21DOC), aldosterone (ALD), testosterone (T), androstenedione (A4), corticosterone (B), 11-deoxycortisol (11DOC), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (Dehydroepiandrosterone sulfate) sulfate, DHEAS), cortisone (Cortisone, E), 18-hydroxycorticosterone (18OHB), pregnenolone-d4, 17-hydroxypregnenolone-d3, 17-hydroxyprogesterone-d8, progesterone-d9, cortisol-d4, 21-deoxycortisol-d8, aldosterone-d7, testosterone-d3, androstenedione-d7, corticosterone-d8, 11-deoxycortisol-d5, dehydroepiandrosterone-d6, dehydroepiandrosterone sulfate-d6, cortisol-d8, 18-hydroxycorticosterone-d4 and the derivatization reagent hydroxylamine hydrochloride undergo derivatization reaction. The specific operation is as follows:

[0151] (1) Hydroxylamine hydrochloride is mixed with 20vt% methanol aqueous solution to prepare a 2mol / L hydroxylamine hydrochloride solution. 100μL of the steroid hormone mixed working solution and 100μL of the mixed internal standard working solution are respectively taken into 1.5mL centrifuge tubes, and 100μL of the 2mol / L hydroxylamine hydrochloride solution is added to the centrifuge tubes respectively. The tubes are shaken and incubated at 60°C for 15min for derivatization (steroid hormones containing carbonyl functional groups undergo oximation reaction with hydroxylamine hydrochloride to obtain derivatives of steroid hormones and hydroxylamine for optimization of mass spectrometry conditions), and a derivatization reaction solution is obtained.

[0152] (2) The derivatization reaction solution obtained in step (1) is detected by high performance liquid chromatography tandem mass spectrometry (LC-MS / MS), and the specific chromatographic conditions are as follows:

[0153] HPLC conditions:

[0154] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min.

[0155] Mass spectrometry conditions:

[0156] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0157] The mass spectrometry parameters such as MRM ion pairs, transmission voltage (RF Lens) and collision voltage (CE) of the above steroid hormone samples and the hydroxylamine derivative hydroxylamine hydrochloride are shown in Table 7. As can be seen from Table 7, 15 steroid hormones and their internal standards, including testosterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, progesterone, 11-deoxycortisol, corticosterone, 17-hydroxypregnenolone, cortisol, cortisol, pregnenolone, 21-deoxycortisol, aldosterone, 18-hydroxycorticosterone, etc., can undergo derivatization reaction with hydroxylamine and have ion pair parameters that can be used for quantitative detection.

[0158] Table 7 Mass spectrometry parameters of carbonyl-containing steroid hormones after derivatization with hydroxylamine hydrochloride

[0159]

[0160] 2.2. Screening of phenolic hydroxyl derivatives

[0161] Screening an optimal derivatization reagent that can react with steroid hormones containing phenolic hydroxyl functional groups. Estradiol, estriol, estradiol-d5, estriol-d3 were reacted with derivatization reagents (dansyl chloride, 1,2-dimethylimidazole-5-sulfonyl chloride or 1,2-dimethylimidazole-4-sulfonyl chloride) respectively.

[0162] (1) Preparation of dansyl chloride solution: 5 mg of dansyl chloride was mixed with 5 mL of acetone to prepare a dansyl chloride solution with a concentration of 1 mg / mL.

[0163] Preparation of 1,2-dimethylimidazole-5-sulfonyl chloride (DMIS) solution: 5 mg of 1,2-dimethylimidazole-5-sulfonyl chloride was mixed with 5 mL of acetone to prepare a 1 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution.

[0164] Preparation of 1,2-dimethylimidazole-4-sulfonyl chloride solution: Mix 5 mg of 1,2-dimethylimidazole-4-sulfonyl chloride with 5 mL of acetone to prepare a 1 mg / mL 1,2-dimethylimidazole-4-sulfonyl chloride solution.

[0165] (2) Take 5 μL of estradiol standard stock solution, 5 μL of estriol standard stock solution, 20 μL of estradiol-d5 standard internal standard stock solution, and 20 μL of estriol-d3 standard internal standard stock solution, respectively, and place them in a 2 mL centrifuge tube. Add 1 mL of methanol to dilute and mix, then take 100 μL of the mixed liquid and mix with 40 μL of A 1 mg / mL derivatization reagent solution (dansyl chloride solution, 1,2-dimethylimidazole-5-sulfonyl chloride solution or 1,2-dimethylimidazole-4-sulfonyl chloride solution) was mixed, and then 30 μL of 50 mmol / L sodium bicarbonate solution was added, and the pH was adjusted to about 10. The mixture was shaken and incubated at 60°C for 15 min for derivatization (steroid hormones containing phenolic hydroxyl functional groups were esterified with dansyl chloride solution or 1,2-dimethylimidazole-5-sulfonyl chloride to obtain steroid hormones and dansyl chloride or 1,2-dimethylimidazole-5-sulfonyl chloride derivatives) to obtain a derivatization reaction solution.

[0166] (3) The derivatization reaction solution obtained in step (2) is detected by high performance liquid chromatography tandem mass spectrometry (LC-MS / MS), and the specific chromatographic conditions are as follows:

[0167] HPLC conditions:

[0168] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min.

[0169] Mass spectrometry conditions:

[0170] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0171] (4) Experimental results:

[0172] (i) The solution after the reaction of estradiol and estriol with 1,2-dimethylimidazole-4-sulfonyl chloride showed no mass spectrometric response, indicating that steroid hormones containing phenolic hydroxyl functional groups may not undergo derivatization reaction with 1,2-dimethylimidazole-4-sulfonyl chloride.

[0173] (ii) The mass spectrometry parameters such as MRM ion pairs, transmission voltage (RF Lens) and collision voltage (CE) of estradiol, estriol and dansyl chloride derivatives are shown in Table 8.

[0174] Table 8 Mass spectrometry parameters of steroid hormones containing phenolic hydroxyl groups and dansyl chloride derivatives

[0175]

[0176] (iii) The mass spectrometry parameters such as MRM ion pairs, transmission voltage (RFLens) and collision voltage (CE) of estradiol, estriol and 1,2-dimethylimidazole-5-sulfonyl chloride are shown in Table 9.

[0177] Table 9 Mass spectrometry parameters of steroid hormones containing phenolic hydroxyl groups and 1,2-dimethylimidazole-5-sulfonyl chloride derivatives

[0178]

[0179]

[0180] From the data in Tables 8 and 9, it can be seen that the fragment ions of dansyl chloride and estrogen derivatives are both 171, which are poorly characteristic. 1,2-dimethylimidazole-5-sulfonyl chloride was selected as the derivatization reagent for steroid hormones containing phenolic hydroxyl groups.

[0181] 2.3. Optimization of estrone-derivative reagents

[0182] Since estrone contains both a carbonyl group and a phenolic hydroxyl group, its properties determine that it can undergo a derivatization reaction with hydroxylamine and 1,2-dimethylimidazole-5-sulfonyl chloride at the same time. Therefore, it is necessary to add hydroxylamine hydrochloride and 1,2-dimethylimidazole-5-sulfonyl chloride solution in sequence for double derivatization.

[0183] (1) Mix hydroxylamine hydrochloride with 20 wt% methanol aqueous solution to prepare a hydroxylamine hydrochloride solution with a concentration of 2 mol / L.

[0184] Preparation of 1,2-dimethylimidazole-5-sulfonyl chloride solution: Mix 1,2-dimethylimidazole-5-sulfonyl chloride with 5 mL of acetone to prepare a 1,2-dimethylimidazole-5-sulfonyl chloride solution with a concentration of 1 mg / mL.

[0185] (2) After diluting the stock solutions of estrone (E1) and estrone-d4, add hydroxylamine hydrochloride solution and incubate. Then add 1,2-dimethylimidazole-5-sulfonyl chloride solution and sodium bicarbonate solution to incubate, and establish the LC-MS / MS conditions optimization of estrone.

[0186] 5 μL of estrone (E1) standard stock solution and 20 μL of estrone-d4 standard internal standard stock solution were placed in a 2 mL centrifuge tube, diluted and mixed with 1 mL of methanol, and then 80 μL of 2 mol / L hydroxylamine hydrochloride solution was added, and incubated at 60°C for 15 min. Then 40 μL of 1 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of 50 mmol / L sodium bicarbonate solution were added, and incubated at 60°C for 15 min to obtain a double derivatization reaction solution.

[0187] (3) The double derivatization reaction solution obtained in step (2) is detected by high performance liquid chromatography tandem mass spectrometry (LC-MS / MS), and the specific chromatographic conditions are as follows:

[0188] HPLC conditions:

[0189] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min.

[0190] Mass spectrometry conditions:

[0191] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0192] The mass spectrometry parameters such as MRM ion pairs, transmission voltage (RF Lens) and collision voltage (CE) of estrone bis-derivatives and estrone-d4 bis-derivatives are shown in Table 10.

[0193] Table 10 Mass spectrometry parameters of estrone bis-derivatives

[0194] Compound Precursor(m / z) Product(m / z) Dwell Time RF Lens CE Estrone 429 365 10 75 25 estrone-d4 433 96 10 75 40

[0195] As can be seen from Table 10, although estrone has hydroxyl and phenolic hydroxyl groups, the derivatization reaction is mainly based on the phenolic hydroxyl group. After estrone (molecular weight 270.37) undergoes a derivatization reaction with 1,2-dimethylimidazole-5-sulfonyl chloride (molecular weight 194.6), one molecule of hydrogen chloride (molecular weight 36.5) is removed, and the M+H peak of the derivative is 429.

[0196] 3. Optimization of pre-treatment conditions

[0197] The sample detected by the present invention is a serum sample, and the sample processing method adopts liquid-liquid extraction followed by derivatization, wherein the derivatization step is the key step. To achieve the double derivatization technology results, it is necessary to first optimize the hydroxylamine derivatization process, and secondly optimize the derivatization process of estradiol, estriol and 1,2-dimethylimidazole-5-sulfonyl chloride. Finally, it is necessary to select the order of adding hydroxylamine and 1,2-dimethylimidazole-5-sulfonyl chloride.

[0198] 3.1. Optimization of derivatization conditions

[0199] Aldosterone (ALD) with low sensitivity was selected as the optimization index. Hydroxylamine hydrochloride standard was dissolved in 20vt% methanol aqueous solution to prepare 0.5mol / L, 1mol / L, and 2mol / L hydroxylamine hydrochloride solutions respectively. The specific operation was as follows:

[0200] 1) Select fresh human serum samples, divide them into 3 portions, 300 μL each, and place them in 2 mL centrifuge tubes;

[0201] 2) 0.3 mL methanol-acetonitrile mixed solution (V 乙腈 :V 甲醇 =9:1) and 1.2 mL of n-hexane, vortexed for 3 min, and centrifuged at 12000 r / min for 5 min for extraction;

[0202] 3) Take the n-hexane extraction layer and place it in a new 2 mL centrifuge tube and blow dry it at 40°C under nitrogen;

[0203] 4) Add 80 μL of 0.5 mol / L, 1 mol / L, and 2 mol / L hydroxylamine hydrochloride solutions to the three dried centrifuge tubes respectively;

[0204] 5) Place the centrifuge tube incubated at 60°C with shaking for 15 min;

[0205] 6) Take out the centrifuge tube and transfer the sample to a 96-well plate for LC-MS / MS analysis. The specific LC-MS / MS chromatographic conditions are as follows:

[0206] HPLC conditions:

[0207] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min;

[0208] Mass spectrometry conditions:

[0209] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0210] The optimization results are as follows Figure 2 As shown, when 2 mol / L hydroxylamine hydrochloride solution was used, the aldosterone response was the highest, but it was not much different from the response at 1 mol / L concentration, so 1 mol / L hydroxylamine hydrochloride solution was selected as the hydroxyl derivatization reagent.

[0211] 3.2. Optimization of derivatization conditions of 1,2-dimethylimidazole-5-sulfonyl chloride

[0212] 3.2.1. Selection of 1,2-dimethylimidazole-5-sulfonyl chloride concentration

[0213] Estrone, estradiol, and estriol were selected as optimization indicators. 1,2-dimethylimidazole-5-sulfonyl chloride standard was dissolved in acetone to prepare 0.5 mg / mL, 1 mg / mL, and 2 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solutions, respectively. The specific operation was as follows:

[0214] 1) Select fresh human serum samples, divide them into 3 portions, 300 μL each, and place them in 2 mL centrifuge tubes;

[0215] 2) 0.3 mL methanol-acetonitrile mixed solution (V 乙腈 :V 甲醇 =9:1) and 1.2 mL of n-hexane, vortexed for 3 min, and centrifuged at 12000 r / min for 5 min for extraction;

[0216] 3) Take the n-hexane extraction layer and place it in a new 2 mL centrifuge tube and blow dry it at 40°C under nitrogen;

[0217] 4) Add 80 μL of 0.5 mg / mL, 1 mg / mL, and 2 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution and 60 μL of 0.1 mol / L sodium bicarbonate solution to the three dried centrifuge tubes respectively;

[0218] 5) Place the centrifuge tube incubated at 60°C with shaking for 15 min;

[0219] 6) Take out the centrifuge tube and transfer the sample to a 96-well plate for LC-MS / MS analysis. The specific LC-MS / MS chromatographic conditions are as follows:

[0220] HPLC conditions:

[0221] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min;

[0222] Mass spectrometry conditions:

[0223] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0224] The optimization results are as follows Figure 3 As shown in the figure, when using different 2 mg / mL concentrations of 1,2-dimethylimidazole-5-sulfonyl chloride solutions, the responses of estrone, estradiol and estriol are the highest, but the difference with the response of 1 mg / mL concentration is not much, so the 1 mg / mL concentration of 1,2-dimethylimidazole-5-sulfonyl chloride solution is selected as the estrone, estradiol and estriol derivatization reagent. Note: Figure 3 Among them, E1 is estrone, E2 is estradiol, E3 is estriol, and DMIS is 1,2-dimethylimidazole-5-sulfonyl chloride.

[0225] 3.2.2 Optimization of the ratio of sodium carbonate solution to sodium bicarbonate solution in buffer

[0226] Since the derivatization reaction of estrone, estradiol and estriol with 1,2-dimethylimidazole-5-sulfonyl chloride solution requires an alkaline environment, sodium carbonate, sodium bicarbonate or a mixture of the two is generally selected to provide an alkaline environment for the derivatization reaction. Sodium carbonate will slowly generate sodium bicarbonate when it comes into contact with carbon dioxide in the air when stored for a long time, so this scheme selects a mixed solution of sodium carbonate and sodium bicarbonate as a buffer for the derivatization reaction.

[0227] 1) Preparation of sodium carbonate and sodium bicarbonate solutions

[0228] Weigh 0.53 g of sodium carbonate, place it in a 50 mL centrifuge tube, add 50 mL of ultrapure water to make a sodium carbonate solution with a concentration of 0.1 mol / L; weigh 0.42 g of sodium bicarbonate, place it in a 50 mL centrifuge tube, add 50 mL of ultrapure water to make a sodium bicarbonate solution with a concentration of 0.1 mol / L.

[0229] 2) Preparation of buffer solution.

[0230] 0.1 mol / L sodium carbonate solution and 0.1 mol / L sodium bicarbonate solution were mixed in different volumes to prepare buffer solutions.

[0231] Buffer 1: The volume ratio of 0.1 mol / L sodium carbonate solution to 0.1 mol / L sodium bicarbonate solution is 8:2;

[0232] Buffer 2: The volume ratio of 0.1 mol / L sodium carbonate solution to 0.1 mol / L sodium bicarbonate solution is 7:3;

[0233] Buffer solution 3: The volume ratio of 0.1 mol / L sodium carbonate solution to 0.1 mol / L sodium bicarbonate solution is 6:4.

[0234] 3) The specific operation of the derivation process is as follows:

[0235] a. Select fresh human serum samples and divide them into 3 portions, 300 μL each, and place them in 2 mL centrifuge tubes; 0.3 mL methanol-acetonitrile mixed solution (V 乙腈 :V 甲醇 =9:1) and 1.2 mL of n-hexane, vortexed for 3 min, and centrifuged at 12000 r / min for 5 min for extraction;

[0236] b. Take the n-hexane extraction layer and place it in a new 2 mL centrifuge tube and blow dry it at 40°C under nitrogen;

[0237] c. Add 80 μL of 1 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution (solvent: acetone) to each of the three dried centrifuge tubes.

[0238] d. Add 60 μL of buffer 1, buffer 2, and buffer 3 to each centrifuge tube;

[0239] e. Place the centrifuge tube in a 60°C shaking incubator for 15 min;

[0240] f. Take out the centrifuge tube and transfer the sample to a 96-well plate for LC-MS / MS analysis. The specific LC-MS / MS chromatographic conditions are as follows:

[0241] HPLC conditions:

[0242] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min;

[0243] Mass spectrometry conditions:

[0244] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0245] The optimization results are as follows Figure 4 As shown in the figure, among the different buffer components, when the ratio of sodium carbonate to sodium bicarbonate is 6:4, estrone, estradiol and estriol respond best, so the ratio of sodium carbonate solution to sodium bicarbonate solution in the buffer is selected to be 6:4. Figure 4 Among them, E1 is estrone, E2 is estradiol, E3 is estriol, and DMIS is 1,2-dimethylimidazole-5-sulfonyl chloride.

[0246] 3.3. Optimization of the order of derivatization agents

[0247] When steroid hormones containing carbonyl groups and steroid hormones containing phenolic hydroxyl groups are treated at the same time, hydroxylamine hydrochloride may affect the derivatization process of estradiol and estriol. Similarly, 1,2-dimethylimidazole-5-sulfonyl chloride solution may inhibit the derivatization reaction of other steroids. Therefore, it is necessary to examine the order of adding hydroxylamine hydrochloride and 1,2-dimethylimidazole-5-sulfonyl chloride so that all steroid hormones can undergo exclusive derivatization reactions.

[0248] (1) The derivatization process is as follows:

[0249] a) Take 0.3 mL of sample (sample with the lowest concentration of the calibrator), place it in a 2 mL centrifuge tube, and add 0.3 mL of methanol-acetonitrile mixed solution (V 乙腈 :V 甲醇 =9:1) and 1.2 mL of n-hexane, vortexed for 3 min, and centrifuged at 12000 r / min for 5 min for extraction;

[0250] b) Take all the n-hexane extraction layers and place them in a new 2 mL centrifuge tube and blow dry at 40°C under nitrogen;

[0251] c) adding 80 μL of 1 mol / L hydroxylamine hydrochloride solution (solvent is 20vt% methanol aqueous solution) to a dry centrifuge tube, and incubating with shaking at 60° C. for 15 min;

[0252] d) Add 40 μL of 1 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of buffer (the volume ratio of 0.1 mol / L sodium carbonate solution to 0.1 mol / L sodium bicarbonate solution is 6:4), incubate at 60°C with shaking for 15 min, and take out the incubated sample.

[0253] e) The incubated sample was centrifuged at 12000 r / min for 3 min, and 100 μL of the supernatant was taken for LC-MS / MS analysis. The specific LC-MS / MS chromatographic conditions were as follows:

[0254] LC-MS / MS detection and analysis, the specific chromatographic conditions are as follows:

[0255] HPLC conditions:

[0256] The chromatographic column is Fenome C8. 100mm×2.1mm; mobile phase A is: 0.1vt% formic acid aqueous solution; mobile phase B is: methanol solution containing 0.1vt% formic acid; elution gradient, specific elution parameters are: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL; acquisition time is 7min;

[0257] Mass spectrometry conditions:

[0258] An electrospray ion source was used, the collection mode was positive ion mode, the spray voltage was 3500-5500 V, the sheath gas pressure was 35-50 Arb, the auxiliary gas pressure was 6-10 Arb, the evaporation temperature was 450-500°C, the ion transfer tube temperature was 350-400°C, and the collection mode was multiple reaction monitoring mode (MRM).

[0259] (2) In order to better optimize the impact of each step of the derivatization reaction on the entire sample processing process, five sample processing methods were designed during the derivatization process:

[0260] Pretreatment method 1: After the sample is extracted with n-hexane and blown dry, 80 μL of hydroxylamine hydrochloride solution is added, incubated with shaking at 60° C. for 15 min, and then sampled and analyzed.

[0261] Pretreatment 2 method: After the sample was extracted with n-hexane and dried, 40 μL of 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of buffer were added, incubated with shaking at 60°C for 15 min, and then sampled and analyzed.

[0262] Pretreatment 3 method: After the sample was extracted with n-hexane and dried, 40 μL of 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of buffer were added, and the mixture was shaken and incubated at 60°C for 15 min. Then, 80 μL of hydroxylamine hydrochloride solution was added, and the mixture was shaken and incubated at 60°C for 15 min, and then the sample was injected for analysis.

[0263] Treatment 4 method: After the sample is extracted with n-hexane and blown dry, 80 μL of hydroxylamine hydrochloride solution is added first, and incubated at 60°C for 15 min with shaking, and then 40 μL of 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of buffer are added, and incubated at 60°C for 15 min with shaking, and then the sample is injected for analysis.

[0264] Pretreatment method 5: After the sample is extracted with n-hexane and dried, 80 μL of hydroxylamine hydrochloride solution, 40 μL of 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of buffer solution are added at the same time, incubated with shaking at 60°C for 15 minutes, and then sampled and analyzed.

[0265] After the samples (calibrator C1, i.e., the sample with the lowest calibrator concentration) were treated with the five pretreatment methods, the peak areas of 18 steroid hormones were collected. The results are shown in Table 11.

[0266] Table 11 Responses (peak areas) of 18 steroid hormones in 5 sample processing methods

[0267]

[0268]

[0269] The experimental results are shown in Table 11. It can be seen from the table that in the method of pretreatment 1, estrogen (estrone, estradiol, estriol) was not detected; in the method of pretreatment 2, testosterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, progesterone, 11-deoxycortisol, corticosterone, 17-hydroxypregnenolone, cortisol, cortisol, pregnenolone, 21-deoxycortisol, aldosterone, and 18-hydroxycorticosterone were not detected; in the method of pretreatment 3, the method of pretreatment 4, and the method of pretreatment 5, all 18 steroid hormones were detected.

[0270] Among them, the responses of cortisol, aldosterone, and 17-hydroxypregnenolone in the pretreatment 3 method were relatively low, significantly lower than those in the pretreatment 1 method. The possible reason is that when the steroid hormones reacted with hydroxylamine, the pH value in the derivatization system was too high, which inhibited the derivatization reaction.

[0271] Among them, the response of estrone in pretreatment 4 was significantly lower than that in pretreatment 2 and pretreatment 3. The possible reason was that the response was low due to the influence of hydroxylamine during the derivatization reaction between estrone and 1,2-dimethylimidazole-5-sulfonyl chloride.

[0272] Among them, almost all steroid hormones in the pre-treatment method 5 had lower responses than those in the pre-treatment method 4. The possible reason is that the addition of two derivatization reagents at the same time destroyed the specificity of the reaction, resulting in the inhibition of the derivatization reaction.

[0273] In summary, the method of pre-treatment 4 is selected as the pre-treatment method of the sample of the present invention.

[0274] 4. Optimization of HPLC-MS conditions

[0275] After the pretreatment conditions are determined in the above-mentioned "3. Optimization of pretreatment conditions", the liquid phase conditions of the 18 steroids, including the chromatographic column, mobile phase, and elution gradient, need to be optimized to achieve the best chromatographic peak response of all compounds and internal standards.

[0276] Since the concentrations of estrogens (estrone, estradiol, estriol) were low, estrone, estradiol, and estriol (all with a concentration of 1 ng / mL and methanol as the solvent) were selected as chromatographic column optimization indicators, and the chromatographic column with the best response was selected.

[0277] In this experiment, 50 μL of different estrogen methanol solutions (estrone, estradiol, and estriol concentrations were 1 ng / mL, and the solvent was methanol) were used as samples, 1 mol / L hydroxylamine hydrochloride solution was used as a hydroxyl derivatization reagent, 1 mg / mL 1,2-dimethylimidazole-5-sulfonyl chloride solution was used as a derivatization reagent for estrone, estradiol, and estriol, and a mixture of 0.1 mol / L sodium carbonate solution and 0.1 mol / L sodium bicarbonate solution in a volume ratio of 6:4 was used as a buffer. Sample treatment method 4 was used for sample treatment (treatment method 4: that is, after the sample was extracted and dried with n-hexane, 80 μL of hydroxylamine hydrochloride solution was first added, and the sample was incubated at 60°C for 15 min, and then 40 μL of 1,2-dimethylimidazole-5-sulfonyl chloride solution and 30 μL of buffer were added, and the sample was incubated at 60°C for 15 min, and then the sample was injected for analysis). LC-MS / MS detection and analysis were performed using the chromatographic conditions under "3. Optimization of pretreatment conditions".

[0278] (1) When other chromatographic conditions remain unchanged, the chromatographic column is selected as Fenome C8 ( 100×2.1mm, 2.6μm) chromatographic column, Fenome C18 ( 100×3mm, 2.6μm) and Waters BEH C18 (2.1mm×50mm, 1.7μm).

[0279] The optimization results are as follows Figure 5 As shown, using Fenome C8 ( 100×2.1mm, 2.6μm) column, the responses of estrone, estradiol and estriol were all high, so Fei Nuo Mei C8 ( 100×2.1mm, 2.6μm) column was selected as the optimal column. Note: In the figure, Kintex C18 is Fenome C18, Kintex C8 is Fenome C8, Waters BEH C18 is Waters BEH C18; in the figure, E1 is estrone, E2 is estradiol, E3 is estriol, and DMIS is 1,2-dimethylimidazole-5-sulfonyl chloride.

[0280] (2) With other chromatographic conditions remaining unchanged, mobile phase A is an aqueous solution containing 0.1 vt% formic acid, and mobile phase B is a methanol solution containing 0.1 vt% formic acid or an acetonitrile solution containing 0.1 vt% formic acid.

[0281] Both methanol and acetonitrile can be used as mobile phases for steroid hormones. Since methanol is relatively cheap, in a more preferred scheme, mobile phase A is selected to be an aqueous solution containing 0.1 vt% formic acid, and mobile phase B is selected to be a methanol solution containing 0.1 vt% formic acid.

[0282] (3) Although testosterone and dehydroepiandrosterone, 11-deoxycortisol, corticosterone, 21-deoxycortisol and other isomers form different characteristic fragment ions after derivatization with hydroxylamine, optimizing the liquid phase gradient to achieve baseline analysis of isomers can enhance the specificity of the method.

[0283] Preferred scheme 1: acquisition time 7min; elution gradient: 0-0.5min, mobile phase B is 10%; 0.5-5.0min, mobile phase B is from 10% to 100%; 5.0-5.1min, mobile phase B is 100% to 10%; 5.1-7.0min, mobile phase B is 10%; injection volume is 20μL.

[0284] Preferred solution 2: acquisition time 6 min; elution gradient: 0-0.5 min, mobile phase B is 35%; 0.5-5.0 min, mobile phase B is from 35% to 100%; 5.0-5.1 min, mobile phase B is 100% to 35%; 5.1-6.0 min, mobile phase B is 35%; injection volume is 20 μL.

[0285] Preferred scheme three: acquisition time 7min; elution gradient: 0-0.5min, mobile phase B is 35%; 0.5-5.0min, mobile phase B is from 35% to 100%; 5.0-5.1min, mobile phase B is 100% to 35%; 5.1-7.0min, mobile phase B is 35%; injection volume is 20μL.

[0286] Preferred scheme 4: acquisition time 7min; elution gradient: 0-0.5min, mobile phase B is 50%; 0.5-5.0min, mobile phase B is 50%-100%; 5.0-5.1min, mobile phase B is 100%-50%; 5.1-7.0min, mobile phase B is 50%; injection volume is 20μL.

[0287] In the preferred scheme 1, the separation degree of testosterone and dehydroepiandrosterone, 11-deoxycortisol, corticosterone, and 21-deoxycortisol is high, but the retention time of 17-hydroxyprogesterone and testosterone, progesterone, and androstenedione is >6.5min. The detection time of at least 8min is required by this scheme. The possible reason is that the initial mobile phase ratio is too low, resulting in excessive retention time of the compound.

[0288] In the preferred scheme 2, the separation degree of testosterone and dehydroepiandrosterone, 11-deoxycortisol, corticosterone, and 21-deoxycortisol is worse than that of the scheme 1, but baseline separation can be achieved. All compounds are ≤6min, among which the retention time of progesterone is 6min, and the equilibrium time is too short.

[0289] In the preferred embodiment 4, testosterone and dehydroepiandrosterone, 11-deoxycortisol, corticosterone, and 21-deoxycortisol cannot achieve baseline separation.

[0290] Therefore, the initial proportion of mobile phase B was set to 35% and the final equilibrium time of the gradient was changed to 2 min, thus obtaining the preferred solution 3. Therefore, the preferred solution 3 was selected as the liquid phase condition.

[0291] (4) The column temperature of this method has little effect on the liquid phase conditions, and the column temperature of the chromatographic column is selected to be 40°C.

[0292] (5) The present invention utilizes double derivatization technology to derivatize all steroid hormones containing carbonyl groups and phenolic hydroxyl groups during sample processing. Therefore, the ion source in the present invention only needs to use the positive ion mode.

[0293] In a preferred embodiment, an electrospray ion source is used, the collection mode is a positive ion mode, the spray voltage is 3500-5500 V, the sheath gas pressure is 35-50 Arb; the auxiliary gas pressure is 6-10 Arb; the evaporation temperature is 450-500°C; the ion transfer tube temperature is 350-400°C, the collection mode is a multiple reaction monitoring mode (MRM), and the collection time is 7 min.

[0294] In a more preferred embodiment, an electrospray ion source is used, the collection mode is positive ion mode, the spray voltage is 3500V, the sheath gas pressure is 40Arb; the auxiliary gas pressure is 10Arb; the evaporation temperature is 450°C; the ion transfer tube temperature is 350°C, the collection mode is multiple reaction monitoring mode (MRM), and the collection time is 7min.

[0295] 5. Preparation of the kit

[0296] The kit components of a steroid hormone are composed of 6 concentrations of calibrators, 2 concentrations of quality control products, internal standard solution, sample extraction solution, protein precipitant, sample adjustment solution, sample enhancement solution 1, sample enhancement solution 2, mobile phase A, and mobile phase B.

[0297] 5.1 Preparation of Calibrators and Quality Controls

[0298] (1) Preparation of standard stock solutions: 18 steroid hormone standard powders were dissolved in the first solvent to prepare individual stock solutions. The specific preparation process is as follows:

[0299] 11-deoxycortisol, dehydroepiandrosterone, cortisol, 18-hydroxycortisol, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, and estriol were accurately weighed, dissolved in the first solvent, and then fixed to volume to prepare a single standard stock solution of 1 mg / mL. Dehydroepiandrosterone sulfate was accurately weighed, dissolved in the first solvent, and then fixed to volume to prepare a single standard stock solution of 2 mg / mL.

[0300] The first solvent used is a methanol solution containing 2,6-di-tert-butyl-4-methylphenol, and the mass volume ratio of 2,6-di-tert-butyl-4-methylphenol to methanol is 1 g:1000 mL.

[0301] (2) Mix bovine serum albumin, antioxidants, preservatives, etc. to prepare a second solvent. Preferably, the second solvent consists of bovine serum albumin, isoascorbic acid, citric acid, 10×PBS buffer, and deionized water; wherein the concentration of bovine serum albumin is 1% (m / v), the concentration of isoascorbic acid is 0.1% (m / v), the concentration of citric acid is 0.1% (m / v), the volume proportion of 10×PBS in the second solvent is 10%, and the remainder is deionized water. The unit of m / v is g / mL.

[0302] (3) Mixing the single standard stock solutions of 18 steroid hormones and adding them into the first solvent to prepare a steroid hormone mixed working solution.

[0303] The mixed working solution is prepared as follows:

[0304] Take 10 μL of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone and testosterone standard stock solutions; 20 μL of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone and dehydroepiandrosterone standard stock solutions; 4 μL of estrone and 18-hydroxycorticosterone standard stock solutions, 5 mL of dehydroepiandrosterone sulfate standard stock solution, and 200 μL of cortisol standard stock solution are placed in a 10 mL volumetric flask, and the first solvent is added to the fixed volume to prepare a mixed working solution of 18 steroid hormones, among which pregnenolone, progesterone, The concentrations of estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were all 1 μg / mL; the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were all 2 μg / mL; the concentrations of estrone and 18-hydroxycorticosterone were both 400 ng / mL; the concentration of dehydroepiandrosterone sulfate was 1 mg / mL, and the concentration of cortisol was 20 μg / mL.

[0305] (4) Mix different volumes of the mixed working solution with the second solvent to prepare calibration products C1, calibration product C2, calibration product C3, calibration product C4, calibration product C5, calibration product C6, quality control products QC1, and quality control products QC2. When the mixed working solution is mixed with the second solvent, the added ratio of the mixed working solution shall not exceed 5% of the total volume.

[0306] The preparation method is shown in Table 12:

[0307] Table 12

[0308]

[0309] Among them, in standard samples C1 to C6, the concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone are the same, and the six concentrations are 0.05ng / mL, 0.125ng / mL, 0.25ng / mL, 1.25ng / mL, 5ng / mL, and 10ng / mL, respectively; the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone are the same, and the six concentrations are 0.1ng / mL, 0.25ng / mL, 0.5ng / mL, 2.5ng / mL, 10ng / mL, 2 0ng / mL; the concentrations of estrone and 18-hydroxycorticosterone are the same, the 6 concentrations are 0.02ng / mL, 0.05ng / mL, 0.1ng / mL, 0.5ng / mL, 2ng / mL, 4ng / mL; the 6 concentrations of dehydroepiandrosterone sulfate are 50ng / mL, 125ng / mL, 250ng / mL, 1250ng / mL, 5000ng / mL, 10000ng / mL; the 6 concentrations of cortisol are 1ng / mL, 2.5ng / mL, 5ng / mL, 25ng / mL, 100ng / mL, 200ng / mL.

[0310] In the quality control products QC1 to QC2, the concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone are the same, and the two concentration points are 0.2 ng / mL and 7.5 ng / mL respectively; the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone are the same, and the two concentration points are 0.4 ng / mL and 15 ng / mL respectively; the concentrations of estrone and 18-hydroxycorticosterone are the same, and the two concentration points are 0.08 ng / mL and 3 ng / mL respectively; the two concentration points of dehydroepiandrosterone sulfate are 200 ng / mL and 7500 ng / mL respectively; the two concentration points of cortisol are: 4 ng / mL and 150 ng / mL respectively.

[0311] After the calibration and quality control products are prepared, they are dispensed into brown vials at a volume of 0.5 mL each and left for freeze-drying.

[0312] 5.2 Preparation of internal standard solution

[0313] (1) 18 steroid hormone internal standard substances are dissolved in a first solvent to prepare individual standard internal standard substance stock solutions.

[0314] Among them, the 18 steroid hormone internal standard substances are pregnenolone-d4, 17-hydroxypregnenolone-d3, 17-hydroxyprogesterone-d8, progesterone-d9, estradiol-d5, estriol-d3, cortisol-d8, 21-deoxycortisol-d8, aldosterone-d7, testosterone-d3, androstenedione-d7, estrone-d4, corticosterone-d8, 11-deoxycortisol-d5, dehydroepiandrosterone-d5, dehydroepiandrosterone sulfate-d6, corticosterone-d8, and 18-hydroxycorticosterone-d4. The specific preparation process is as follows:

[0315] Accurately weigh 11-deoxycortisol-d5, dehydroepiandrosterone-d6, cortisol-d8, and 18-hydroxycorticosterone-d4, each with a standard specification of 1 mg. Add 1 mL of the first solvent to dissolve them, and then prepare a single standard internal standard stock solution of 1 mg / mL.

[0316] Accurately weigh 2 mg of dehydroepiandrosterone sulfate-d6 and add it to the first solvent to dissolve it to prepare a 2 mg / mL single standard internal standard stock solution.

[0317] Precisely weigh pregnenolone-d4, 17-hydroxypregnenolone-d3, 17-hydroxyprogesterone-d8, progesterone-d9, cortisol-d4, 21-deoxycortisol-d8, aldosterone-d7, testosterone-d3, androstenedione-d7, corticosterone-d 8、 Estrone-d4, estradiol-d5, and estriol-d3 were respectively added to the first solvent for dissolution to prepare single standard internal standard stock solutions of 100 μg / mL.

[0318] The first solvent is a methanol solution containing 2,6-di-tert-butyl-4-methylphenol, and the mass volume ratio of 2,6-di-tert-butyl-4-methylphenol to methanol is 1 g:1000 mL.

[0319] (2) Preparation of internal standard solution: Mix the standard internal standard stock solutions of 18 steroid hormones and dilute them with a third solvent to form an internal standard solution. The third solvent is a mixed solvent of methanol, acetonitrile and isopropanol in a volume ratio of 3:6:1. The specific preparation process is as follows:

[0320] Take 100 μL of 11-deoxycortisol-d5, cortisol-d8 and 18-hydroxycortisol-d4 standard internal standard stock solutions, 500 μL of dehydroepiandrosterone-d6 standard internal standard stock solution and 1 mL of dehydroepiandrosterone sulfate-d6, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 standard internal standard stock solutions, place them in a 500 mL reagent bottle, and use a third The solvent was fixed to volume to prepare a mixed internal standard working solution; wherein the concentration of 11-deoxycortisol-d5, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, corticosterone-d8, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, 18-hydroxycorticosterone-d4, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 was 200 ng / mL, the concentration of dehydroepiandrosterone-d6 was 1 μg / mL, and the concentration of dehydroepiandrosterone sulfate-d6 was 4 μg / mL.

[0321] After the internal standard solution is prepared, dispense 2 mL into brown vials.

[0322] 5.3 Preparation of sample extract

[0323] One or more of n-hexane, methyl tert-butyl ether, and ethyl acetate are prepared into a sample extract. In a preferred embodiment, n-hexane is selected as the sample extract. The preparation process is to pack n-hexane into brown reagent bottles every 120 mL to obtain the sample extract components.

[0324] 5.4 Preparation of protein precipitant

[0325] The protein precipitant is obtained by mixing acetonitrile and methanol. Preferably, the protein precipitant is a mixed solvent with a volume ratio of acetonitrile to methanol of 9: 1. The protein precipitant is dispensed into brown reagent bottles at 30 mL each to obtain a protein precipitant component.

[0326] 5.5. Preparation of sample enhancement solution 1

[0327] Hydroxylamine hydrochloride is dissolved in a fourth solvent to prepare a sample enhancement solution 1, and each 15 mL is dispensed into a brown reagent bottle. In a preferred embodiment, the concentration of the hydroxylamine hydrochloride solution is selected from any one of 0.5 mol / L, 1 mol / L, 2 mol / L, and 5 mol / L, and the fourth solvent is a 10vt% to 20vt% methanol aqueous solution or a 10vt% to 20vt% acetonitrile aqueous solution.

[0328] More preferably, the concentration of the hydroxylamine hydrochloride solution is 1 mol / L, and the fourth solvent is a 20vt% methanol aqueous solution. After the preparation is completed, 1 portion of the sample enhancement solution is packed in a brown reagent bottle for every 15 mL.

[0329] 5.6. Preparation of sample enhancement solution 2

[0330] 1,2-dimethylimidazole-5-sulfonyl chloride was prepared with the fifth solvent to form a sample enhancement solution 2, and each 5 mL solution was dispensed into brown penicillin bottles.

[0331] The concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the sample enhancement solution 2 is selected from any one of 0.2 mg / mL, 0.5 mg / mL, 1 mg / mL, 2 mg / mL, and 5 mg / mL, and the fifth solvent is selected from acetone or ethyl acetate. More preferably, the concentration of the 1,2-dimethylimidazole-5-sulfonyl chloride solution is 1 mg / mL, and the fifth solvent is acetone. After the preparation is completed, each 5 mL is packaged in a brown penicillin bottle.

[0332] 5.7 Preparation of sample conditioning solution

[0333] Add the weighed sodium bicarbonate and sodium carbonate into appropriate amount of deionized water respectively, stir thoroughly until dissolved, prepare 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution respectively, mix the sodium carbonate solution and the sodium bicarbonate solution in a certain proportion, prepare the sample adjustment solution, and dispense 5 mL each into brown penicillin bottles.

[0334] Preferably, the volume ratio of 0.1 mol / L sodium carbonate aqueous solution to 0.1 mol / L sodium bicarbonate aqueous solution is 1:9 to 9:1, and more preferably, the volume ratio of 0.1 mol / L sodium carbonate aqueous solution to 0.1 mol / L sodium bicarbonate aqueous solution is 6:4, which is prepared into a sample adjustment solution and packaged in brown vials of 5 mL each.

[0335] 5.8. Preparation of mobile phase A and mobile phase B

[0336] Mix formic acid with water to prepare a 0.1 vt% formic acid aqueous solution as mobile phase A; mix formic acid with methanol to prepare a methanol solution containing 0.1 vt% formic acid as mobile phase B; mobile phase A and mobile phase B are respectively dispensed in reagent bottles at 0.5 L each.

[0337] 5.9. Drying of test kit components

[0338] 6 calibrators and 2 quality control products were respectively packaged in 5 mL brown vials at 0.5 mL each and placed in a freeze dryer for freeze drying. The internal standard solution, sample extract, protein precipitant, sample enhancement solution 1, sample enhancement solution 2, sample adjustment solution, mobile phase A, and mobile phase B did not need to be dried, and the liquid components were sufficient.

[0339] In a preferred embodiment, the calibrator and the quality control product are freeze-dried using the same freeze-drying process, and the freeze-drying process includes a pre-freezing stage, sublimation drying and analytical drying in sequence; the operating conditions of the pre-freezing stage are shown in Table 1; the operating conditions of the sublimation drying are shown in Table 2; and the operating conditions of the analytical drying are shown in Table 3.

[0340] In a more preferred embodiment, the calibrator and the quality control product are freeze-dried using the same freeze-drying process, which sequentially includes a pre-freezing stage, sublimation drying and analytical drying; the operating conditions of the pre-freezing stage are shown in Table 4; the operating conditions of the sublimation drying are shown in Table 5; and the operating conditions of the analytical drying are shown in Table 6.

[0341] The 6 freeze-dried calibrators and 2 quality control products were assembled with an internal standard solution, a sample extract, a protein precipitant, a sample enhancement solution 1, a sample enhancement solution 2, a sample adjustment solution, a mobile phase A, and a mobile phase B, and stored at -20°C to obtain a steroid hormone detection kit.

[0342] 6. Sample processing

[0343] (1) taking out the kit (each reagent in the kit is prepared using the above-mentioned optimal parameters) from -20°C, returning it to room temperature, and then taking out each component in the kit;

[0344] (2) Add 0.5 mL of ultrapure water to each of the six calibrators and two quality control bottles, shake for 30 seconds, and set aside;

[0345] (3) Take 0.3 mL of each calibrator, each quality control product, and the serum sample to be tested and place them in a 2 mL centrifuge tube. Add 20 μL of internal standard solution to each sample and shake for 1 min.

[0346] (4) Add 0.3 mL of protein precipitant and 1.2 mL of sample extract to each centrifuge tube and vortex for 3 min at 12000 rpm. -1 Extraction was performed by centrifugation for 5 min;

[0347] (5) Place the supernatant in a new 2 mL centrifuge tube and blow dry with nitrogen at 40 °C;

[0348] (6) Add 80 μL of sample enhancement solution 1 to each dried centrifuge tube and incubate at 60°C with shaking for 15 min;

[0349] (7) Add 40 μL of sample enhancement solution 2 and 30 μL of sample conditioning solution to each centrifuge tube, and incubate at 60°C with shaking for 15 min;

[0350] (8) Take out the incubated samples and rotate them at 12000 r / min-1 Centrifuge for 3 min, take 100 μL of the supernatant and place it in a vial liner or a 96-well plate;

[0351] (9) placing the injection vial liner or the 96-well plate in the automatic sample injector of the liquid chromatograph, and equilibrating the chromatographic column with mobile phase A and mobile phase B for LC-MS / MS detection;

[0352] Among them, the chromatographic conditions for LC-MS / MS detection are as follows:

[0353] Liquid chromatography conditions: Chromatographic column: Fei Nuo Mei C8 ( 100×2.1mm, 2.6μm); column temperature: 40℃; mobile phase A: aqueous solution containing 0.1vt% formic acid; mobile phase B: methanol solution containing 0.1vt% formic acid; gradient elution; elution gradient: 0~0.5min, mobile phase B is 35%; 0.5~5.0min, mobile phase B is from 35% to 100%; 5.0~5.1min, mobile phase B is 100% to 35%; 5.1~7.0min, mobile phase B is 35%; injection volume is 20μL; acquisition time is 7min;

[0354] Mass spectrometry conditions: electrospray ion source, positive ion mode, spray voltage 3500 V, sheath gas pressure 40 Arb, auxiliary gas pressure 10 Arb, evaporation temperature 450 ° C, ion transfer tube temperature 350 ° C, multiple reaction monitoring (MRM) mode, acquisition time 7 min.

[0355] 7. Test kit performance verification

[0356] The extracted ion chromatograms of 18 steroid hormones at the quantitative limit concentration are shown in Figure 2. Figure 6 shown.

[0357] The performance of the steroid hormone kit of the present invention was verified by designing experiments on linearity, quantitative limit, precision, accuracy, etc. The verification results are shown in Tables 13 and 14, and the chromatogram at the quantitative limit concentration is shown in Table 13. Figure 6 .

[0358] (1) Linearity and quantitative lower limit verification

[0359] The internal standard quantitative method was adopted, and the concentration ratio of the standard substance in the calibrator to the internal standard substance in the internal standard solution was used as the X-axis, and the peak area ratio of the standard substance in the calibrator to the internal standard substance in the internal standard solution was used as the Y-axis to establish a standard curve and detect the sample at the lower limit of quantitative concentration (calibrator C1). Each sample was tested 5 times. The linearity and quantitative limit parameters of the kit, such as linear range, slope, correlation coefficient r, mean of the lower limit of quantitative concentration, signal-to-noise ratio (S / N), coefficient of variation (CV%) and accuracy are shown in Figure 7The results showed that this method can achieve accurate detection at the lower limit of quantification (LLOQ) concentration and has a good linear relationship within the linear range.

[0360] (2) Precision verification

[0361] The stock solutions of 18 steroid hormones were added to normal human serum to prepare precision verification samples of high and low concentrations. The concentrations of 18 steroid hormones were quantitatively determined by the steroid hormone kit using the isotope internal standard method. Each concentration was repeated 5 times, one analysis batch per day, and the test was continued for three days. The statistical results of intra-batch precision and inter-batch precision are shown in Table 13.

[0362] Table 13 Precision results of 18 steroid hormone test kits (intra-batch and inter-batch precision)

[0363]

[0364]

[0365] (3) Accuracy verification

[0366] The working solutions of 18 steroid hormones were added to human serum, one of which was not added with standard substances, and the other three were added with high, medium and low concentrations of recovery verification standards, and the concentrations of the 18 steroid hormones were quantitatively determined by the isotope internal standard method using a steroid hormone kit. Each concentration was repeated 5 times, and the recovery results were calculated. The recovery results are shown in Table 14. The results showed that the recovery results of the spiked 18 steroid hormones in serum were between 68% and 121.6%.

[0367] Table 14 Accuracy (recovery rate) results of 18 steroid hormone kits

[0368]

[0369]

[0370]

[0371] The present invention provides a kit and method for simultaneously detecting 18 steroid hormones based on double derivatization technology. There are many methods and approaches to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.

Claims

1. A kit for simultaneously detecting 18 steroid hormones based on double derivatization technology, characterized in that: The steroid hormones are 11-deoxycortisol, dehydroepiandrosterone, corticosterone, 18-hydroxycorticosterone, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, estriol and dehydroepiandrosterone sulfate; The kit comprises the following reagents: (1) Series of Calibrators: The series of calibration products are freeze-dried products of series of calibration product working solutions with six different concentration levels, and the series of calibration product working solutions are calibration product working solutions with six different concentration levels prepared by diluting a steroid hormone mixed working solution of known concentration with a second solvent; Among them, the six concentration levels of the calibrator working solution are: The concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were the same, and the six concentrations were 0.05 ng / mL, 0.125 ng / mL, 0.25 ng / mL, 1.25 ng / mL, 5 ng / mL, and 10 ng / mL; The concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were the same, and the six concentrations were 0.1 ng / mL, 0.25 ng / mL, 0.5 ng / mL, 2.5 ng / mL, 10 ng / mL, and 20 ng / mL; The concentrations of estrone and 18-hydroxycorticosterone were the same, and the six concentrations were 0.02 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.5 ng / mL, 2 ng / mL, and 4 ng / mL; The six concentrations of dehydroepiandrosterone sulfate are: 50ng / mL, 125ng / mL, 250ng / mL, 1250ng / mL, 5000ng / mL, and 10000ng / mL; The six concentrations of cortisol were: 1 ng / mL, 2.5 ng / mL, 5 ng / mL, 25 ng / mL, 100 ng / mL, and 200 ng / mL; (2) Series of quality control products: The series of quality control products are freeze-dried products of a series of quality control product working solutions with two different concentration levels, and the series of quality control product working solutions are quality control product working solutions with two different concentration levels prepared by diluting a steroid hormone mixed working solution of known concentration with a second solvent; Among them, the two concentration levels of the quality control working solution are: The concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone, and testosterone were the same, with two concentration points of 0.2 ng / mL and 7.5 ng / mL, respectively; The concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone, and dehydroepiandrosterone were the same, with two concentration points of 0.4 ng / mL and 15 ng / mL, respectively; The concentrations of estrone and 18-hydroxycorticosterone were the same, with the two concentration points being 0.08 ng / mL and 3 ng / mL, respectively; The two concentration points of dehydroepiandrosterone sulfate were 200 ng / mL and 7500 ng / mL; The 2 concentration points of cortisol are: The 2 concentration points of cortisol are 4ng / mL and 150ng / mL; (3) Internal standard solution: The internal standard solution is a mixture of various steroid hormone standard internal standard stock solutions of known concentrations, and is diluted with a third solvent to form an internal standard solution; In the internal standard solution, the concentrations of 11-deoxycortisol-d5, 17-hydroxyprogesterone-d8, corticosterone-d8, androstenedione-d7, testosterone-d3, corticosterone-d8, estrone-d4, estradiol-d5, estriol-d3, pregnenolone-d4, aldosterone-d7, 18-hydroxycorticosterone-d4, progesterone-d9, 21-deoxycortisol-d8, 17-hydroxypregnenolone-d3, and cortisol-d4 are 200 ng / mL, the concentration of dehydroepiandrosterone-d6 is 1 μg / mL, and the concentration of dehydroepiandrosterone sulfate-d6 is 4 μg / mL; (4) Sample extraction solution: any one or a combination of n-hexane, methyl tert-butyl ether and ethyl acetate; (5) Protein precipitant: a mixed solvent of acetonitrile and methanol in any volume ratio; (6) Sample conditioning solution: a mixed solution of 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution in a volume ratio of 1:9 to 9:1; (7) Sample enhancement solution 1: hydroxylamine hydrochloride solution, the solvent in the solution is 10vt% to 20vt% methanol aqueous solution or 10vt% to 20vt% acetonitrile aqueous solution, and the concentration of hydroxylamine hydrochloride in the solution is 0.5mol / L to 5mol / L; (8) Sample enhancement solution 2: 1,2-dimethylimidazole-5-sulfonyl chloride solution, the solvent in the solution is acetone or ethyl acetate, and the concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the solution is 0.2 mg / mL to 5 mg / mL; (9) Mobile phase A: 0.1 vt% formic acid aqueous solution; (10) Mobile phase B: methanol solution containing 0.1 vt% formic acid or acetonitrile solution containing 0.1 vt% formic acid; The freeze-drying process of the calibrator and the quality control product includes a pre-freezing stage, sublimation drying and analytical drying in sequence; The operating conditions of the pre-freezing stage are as follows: The operating conditions of the sublimation drying are as follows: The operating conditions of the analytical drying are as follows: or, The freeze-drying process of the calibrator and the quality control product includes a pre-freezing stage, sublimation drying and analytical drying in sequence; The operating conditions of the pre-freezing stage are as follows: The operating conditions of the sublimation drying are as follows: The operating conditions of the analytical drying are as follows:

2. The kit according to claim 1, characterized in that The second solvent consists of bovine serum albumin, an antioxidant, a preservative, a buffer and water; the antioxidant is isoascorbic acid; the preservative is citric acid; the buffer is PBS buffer; preferably, the second solvent consists of 1-5% bovine serum albumin, 0.05%-2% isoascorbic acid, 0.05%-2% citric acid, 10% 10×PBS buffer and deionized water; further preferably, the second solvent consists of 1% bovine serum albumin, 0.1% isoascorbic acid, 0.1% citric acid, 10% 10×PBS buffer and deionized water; the third solvent is a mixed solvent of methanol, acetonitrile and isopropanol in any volume ratio; preferably, the third solvent is a mixed solvent of methanol, acetonitrile and isopropanol in a volume ratio of 3:6:

1.

3. The kit according to claim 1, characterized in that The steroid hormone mixed working solution of known concentration is prepared as follows: 11-deoxycortisol, dehydroepiandrosterone, cortisol, 18-hydroxycortisol, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, and estriol were accurately weighed, dissolved in the first solvent, and prepared into 1 mg / mL standard stock solutions; dehydroepiandrosterone sulfate was accurately weighed, dissolved in the first solvent, and prepared into 2 mg / mL standard stock solutions; The above-mentioned standard stock solutions are then prepared into a steroid hormone mixed working solution with the first solvent; the concentrations of pregnenolone, progesterone, estradiol, estriol, 21-deoxycortisol, aldosterone and testosterone in the steroid hormone mixed working solution are all 1 μg / mL; the concentrations of 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, corticosterone, androstenedione, corticosterone and dehydroepiandrosterone are all 2 μg / mL; the concentrations of estrone and 18-hydroxycorticosterone are both 400 ng / mL; the concentration of dehydroepiandrosterone sulfate is 1 mg / mL, and the concentration of cortisol is 20 μg / mL.

4. The kit according to claim 1, characterized in that The known concentrations of various steroid hormone standard internal standard stock solutions are prepared as follows: 11-deoxycortisol-d5, dehydroepiandrosterone-d6, cortisol-d8, and 18-hydroxycortisol-d4 were accurately weighed and dissolved in the first solvent to prepare 1 mg / mL standard internal standard stock solutions; dehydroepiandrosterone sulfate-d6 was accurately weighed and dissolved in the first solvent to prepare 2 mg / mL standard internal standard stock solutions; pregnenolone-d4, 17-hydroxypregnenolone-d3, 17-hydroxyprogesterone-d8, progesterone-d9, cortisol-d4, 21-deoxycortisol-d8, aldosterone-d7, testosterone-d3, androstenedione-d7, corticosterone-d 8、 Estrone-d4, estradiol-d5, and estriol-d3 are respectively dissolved in the first solvent and prepared into 100 μg / mL standard internal standard stock solutions; The above-mentioned internal standard stock solutions are mixed and diluted with the third solvent to obtain the internal standard solution.

5. The kit according to claim 3 or 4, characterized in that The first solvent is a methanol solution containing 2,6-di-tert-butyl-4-methylphenol; preferably, in the methanol solution containing 2,6-di-tert-butyl-4-methylphenol, the mass volume ratio of 2,6-di-tert-butyl-4-methylphenol to methanol is 1g:1000mL.

6. The kit according to claim 1, characterized in that The series of calibration product working solutions and the series of quality control product working solutions are freeze-dried respectively to obtain the series of calibration products and the series of quality control products.

7. The kit according to claim 1, characterized in that The sample extract is n-hexane; the protein precipitant is a mixed solvent of acetonitrile and methanol in a volume ratio of 9:1; the sample conditioning solution is a mixed solution of 0.1 mol / L sodium carbonate aqueous solution and 0.1 mol / L sodium bicarbonate aqueous solution in a volume ratio of 6:4; the sample enhancement solution 1 is a hydroxylamine hydrochloride solution, the solvent in the solution is a 20vt% methanol aqueous solution, and the concentration of hydroxylamine hydrochloride in the solution is 1 mol / L; the sample enhancement solution 2 is a 1,2-dimethylimidazole-5-sulfonyl chloride solution, the solvent in the solution is acetone, and the concentration of 1,2-dimethylimidazole-5-sulfonyl chloride in the solution is 1 mg / mL; the mobile phase A is a 0.1vt% formic acid aqueous solution; the mobile phase B is a methanol solution containing 0.1vt% formic acid; The freeze-drying process of the calibrator and the quality control product includes a pre-freezing stage, sublimation drying and analytical drying in sequence; The operating conditions of the pre-freezing stage are as follows: The operating conditions of the sublimation drying are as follows: The operating conditions of the analytical drying are as follows:

8. Use of the kit according to any one of claims 1 to 7 for simultaneously detecting 18 steroid hormones in serum using high performance liquid chromatography tandem mass spectrometry.

9. The use according to claim 8, characterized in that: The 18 steroid hormones are 11-deoxycortisol, dehydroepiandrosterone, corticosterone, 18-hydroxycorticosterone, pregnenolone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, progesterone, cortisol, 21-deoxycortisol, aldosterone, testosterone, androstenedione, corticosterone, estrone, estradiol, estriol and dehydroepiandrosterone sulfate; Before the determination of steroid hormones, the series of calibrators are reconstituted with ultrapure water according to the corresponding six concentration levels of the series of calibrator working solutions to obtain series of calibrator working solutions; the series of quality control products are reconstituted with ultrapure water according to the corresponding two concentration levels of the series of quality control working solutions to obtain series of quality control working solutions.

10. The use according to claim 9, characterized in that: The steps for testing 18 steroid hormones in serum include: The internal standard solution is added to the series of calibration solution, the series of quality control solution and the serum sample respectively; then a protein precipitant and a sample extract are added to each sample, centrifuged and the supernatant is taken; the supernatant is blown dry, and after adding the sample enhancement solution 1, an oximation reaction is carried out at 55-65° C.; the sample enhancement solution 2 and the sample adjustment solution are continuously added, and an esterification reaction is carried out at 55-65° C.; after the reaction is completed, the reaction solution is centrifuged, the supernatant is taken, and the supernatant is subjected to LC-MS / MS detection.

11. The use according to claim 10, characterized in that: The chromatographic conditions for the LC-MS / MS detection are as follows: Liquid chromatography conditions: Chromatographic column: Fei Nuo Mei C8 ( 100×2.1mm, 2.6μm), Fenome C18 ( 100×3mm, 2.6μm) or Waters BEH C18 (2.1mm×50mm, 1.7μm); column temperature: 40℃; mobile phase A: aqueous solution containing 0.1vt% formic acid; mobile phase B: methanol solution containing 0.1vt% formic acid or acetonitrile solution containing 0.1vt% formic acid; gradient elution; elution gradient: 0~0.5min, mobile phase B is 35%; 0.5~5.0min, mobile phase B is from 35% to 100%; 5.0~5.1min, mobile phase B is 100% to 35%; 5.1~7.0min, mobile phase B is 35%; injection volume is 20μL; acquisition time is 7min; Mass spectrometry conditions: electrospray ion source, collection mode is positive ion mode, spray voltage is 3500-5500 V, sheath gas pressure: 35-50 Arb; auxiliary gas pressure: 6-10 Arb; evaporation temperature: 450-500 ° C; ion transfer tube temperature: 350-400 ° C, collection mode is multiple reaction monitoring mode, collection time 7 min; Preferably, the chromatographic conditions for the LC-MS / MS detection are as follows: Liquid chromatography conditions: Chromatographic column: Fei Nuo Mei C8 ( 100×2.1mm, 2.6μm); column temperature: 40℃; mobile phase A: aqueous solution containing 0.1vt% formic acid; mobile phase B: methanol solution containing 0.1vt% formic acid; gradient elution; elution gradient: 0~0.5min, mobile phase B is 35%; 0.5~5.0min, mobile phase B is from 35% to 100%; 5.0~5.1min, mobile phase B is 100% to 35%; 5.1~7.0min, mobile phase B is 35%; injection volume is 20μL; acquisition time is 7min; The mass spectrometry chromatography conditions are as follows: an electrospray ion source is used, the collection mode is a positive ion mode, the spray voltage is 3500V, and the sheath gas pressure is 40Arb; Auxiliary gas pressure: 10Arb; evaporation temperature: 450°C; ion transfer tube temperature: 350°C, acquisition mode is multiple reaction monitoring mode, acquisition time is 7min.

Citation Information

Patent Citations

  • Kit for detecting 10 kinds of steroid hormones in serum through high performance liquid chromatography tandem mass spectrum technique

    CN104807920A

  • Method for detecting 10 kinds of steroid hormones in serum through high performance liquid chromatography tandem mass spectrum technique

    CN104807921A

  • Steroid hormone detection kit

    CN110927289A

  • Method and kit for simultaneously detecting multiple steroid hormones in blood sample

    CN111175419A

  • Kit for detecting 12 steroid hormones in serum by using ultra-high performance liquid chromatography-tandem mass spectrometry technology

    CN111398447A